Effectiveness of short treatment duration for carbapenemase-producing Enterobacterales in bloodstream-infections: A retrospective cohort study

Int J Antimicrob Agents. 2024 Nov;64(5):107318. doi: 10.1016/j.ijantimicag.2024.107318. Epub 2024 Sep 2.

Abstract

Objective: We analyse the effectiveness of short courses of adequate treatment in patients with episodes of carbapenemase-producing Enterobacterales bloodstream-infections (CPE-BSI).

Methods: Patients with first monomicrobial CPE-BSI episodes who received ≥72 h of appropriate treatment from 2014-2022 were selected. Detection of CPE was established on the basis of phenotypic antibiogram and confirmation by PCR and/or immunochromatographic methods. Patients were classified in short treatment group (STG) those who received 3-10 days of appropriate treatment, and long treatment (LTG) those receiving >10 days. Unfavourable outcome consisted in a composite of global 30-day mortality and/or persistent bacteremia and/or recurrent bacteremia. Inverse probability of treatment weighting (IPTW) analysis was performed to compare the outcome between the two study groups.

Results: We included 105 CPE-BSI episodes: 99 were caused by OXA-48-like, 4 VIM and 2 KPC carbapenemases. Thirty-nine patients (37.1%) were included in the STG and 66 (62.9%) in LTG. The STG group presented frequent treatment with ceftazidime-avibactam (43.6% vs. 24.2%, P = 0.03) and lower in-hospital stay (21 days vs. 32 days, P = 0.02). Overall, 28 patients (26.7%) presented unfavourable outcome: IPTW analysis showed no differences in the outcome between STG to LTG groups (24.2% vs. 30.8%, weighted-risk difference 6.6%, P = 0.44). Patients with unfavourable outcome presented more frequently source other than urinary-biliary (46.4% vs. 23.4%, P = 0.02), received less frequently ceftazidime-avibactam (14.3% vs. 37.7%, P = 0.02) and presented frequently with absence of source control when indicated (28.6% vs. 13.0%, P = 0.06).

Conclusions: Short treatment durations for CPE-BSI episodes may be effective, as long as they are appropriate and source control is performed.

Keywords: Carbapenemase-producing Enterobacterales bloodstream-infections; Mortality; Short treatment duration.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents* / therapeutic use
  • Azabicyclo Compounds / therapeutic use
  • Bacteremia* / drug therapy
  • Bacteremia* / microbiology
  • Bacterial Proteins* / genetics
  • Carbapenem-Resistant Enterobacteriaceae* / drug effects
  • Ceftazidime* / therapeutic use
  • Drug Combinations
  • Enterobacteriaceae Infections* / drug therapy
  • Enterobacteriaceae Infections* / microbiology
  • Female
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Retrospective Studies
  • Treatment Outcome
  • beta-Lactamases* / metabolism

Substances

  • Anti-Bacterial Agents
  • carbapenemase
  • beta-Lactamases
  • Bacterial Proteins
  • Ceftazidime
  • avibactam, ceftazidime drug combination
  • Drug Combinations
  • Azabicyclo Compounds